Cannabis and mental illness: a review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Agrawal A, Pergadia ML, Lynskey MT (2008) Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions? Am J Addict 17:199–208
Andréasson S, Engström A, Allebeck P, Rydberg U (1987) Cannabis and schizophrenia a longitudinal study of swedish conscripts. Lancet 330:1483–1486
APA (2013) Diagnostic and statistical manual of mental disorders. APA, Washington, DC
Baggio S, N’goran AA, Deline S, Studer J, Dupuis M, Henchoz Y, Mohler-Kuo M, Daeppen JB, Gmel G (2014) Patterns of cannabis use and prospective associations with health issues among young males. Addiction 109:937–945
Bahorik AL, Leibowitz A, Sterling SA, Travis A, Weisner C, Satre DD (2017) Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord 213:168–171
Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, Lefever TW, Wiley JL (2016) Tasty thc: promises and challenges of cannabis edibles. Methods report. RTI Press, Research Triangle
Bergamaschi MM, Queiroz RHC, Chagas MHN, De Oliveira DCG, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219
Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO (2013) Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict 22:277–284
Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Martin AMS, Thurnauer H, Davies A, D’Souza DC (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 235:1923–1932
Bonn-Miller MO, Babson KA, Vandrey R (2014) Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with ptsd. Drug Alcohol Depend 136:162–165
Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA (2014) Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse 40:23–30
Bossong MG, Jansma JM, van Hell HH, Jager G, Oudman E, Saliasi E, Kahn RS, Ramsey NF (2012) Effects of δ9-tetrahydrocannabinol on human working memory function. Biol Psychiatry 71:693–699
Brown AS, Lau FS (2016) A review of the epidemiology of schizophrenia. In: Pletnikov MV, Waddington JL (eds) Modeling the psychopathological dimensions of schizophrenia: from molecules to behavior, vol 359. Academic Press, San Diego, pp 1555–1564
Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC, Lewinsohn PM (2008) Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 42:230–239
Buckner JD, Zvolensky MJ, Ecker AH, Jeffries ER (2016) Cannabis craving in response to laboratory-induced social stress among racially diverse cannabis users: the impact of social anxiety disorder. J Psychopharmacol 30:363–369
Budney AJ, Hughes JR, Moore BA, Vandrey R (2004) Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161:1967–1977
Bujarski SJ, Galang JN, Short NA, Trafton JA, Gifford EV, Kimerling R, Vujanovic AA, McKee LG, Bonn-Miller MO (2016) Cannabis use disorder treatment barriers and facilitators among veterans with ptsd. Psychol Addict Behav 30:73
Cameron C, Watson D, Robinson J (2014) Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol 34:559
Government of Canada (2017) Canadian cannabis survey 2017—summary. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/canadian-cannabissurvey-2017-summary.html . Accessed 10 June 2018
Carey CE, Agrawal A, Bucholz KK, Hartz SM, Lynskey MT, Nelson EC, Bierut LJ, Bogdan R (2016) Associations between polygenic risk for psychiatric disorders and substance involvement. Front Genet 7:149
Chambers RA, Krystal JH, Self DW (2001) A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50:71–83
Charilaou P, Agnihotri K, Garcia P, Badheka A, Frenia D, Yegneswaran B (2017) Trends of cannabis use disorder in the inpatient: 2002 to 2011. Am J Med 130:678.e677–687.e677
Compton WM, Han B, Jones CM, Blanco C, Hughes A (2016) Marijuana use and use disorders in adults in the USA, 2002–14: analysis of annual cross-sectional surveys. Lancet Psychiatry 3:954–964
Conway KP, Swendsen J, Husky MM, He J-P, Merikangas KR (2016) Association of lifetime mental disorders and subsequent alcohol and illicit drug use: results from the national comorbidity survey–adolescent supplement. J Am Acad Child Adolesc Psychiatry 55:280–288
Copeland J, Rooke S, Swift W (2013) Changes in cannabis use among young people: impact on mental health. Curr Opin Psychiatry 26:325–329
Cougle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA (2011) Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav 25:554
Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ (2015) Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: an analysis of the national epidemiological survey on alcohol and related conditions (nesarc). J Psychiatr Res 66:135–141
Crean RD, Crane NA, Mason BJ (2011) An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 5:1
Crippa JA, Guimarães FS, Campos AC, Zuardi AW (2018) Translational investigation of the therapeutic potential of cannabidiol (cbd): toward a new age. Front Immunol. https://doi.org/10.3389/fimmu.2018.02009
Curran H, Morgan C (2014) Desired and undesired effects of cannabis on the human mind and psychological well-being. Handbook of cannabis. Oxford University Press, Oxford, pp 647–660
Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH (2016) Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17:293
D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29:1558
D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608
Danielsson A-K, Lundin A, Agardh E, Allebeck P, Forsell Y (2016) Cannabis use, depression and anxiety: a 3-year prospective population-based study. J Affect Disord 193:103–108
Davis GP, Compton MT, Wang S, Levin FR, Blanco C (2013) Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the national epidemiologic survey on alcohol and related conditions. Schizophr Res 151:197–202
Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC (2013) The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 108:124–133
Degenhardt L, Hall W, Lynskey M (2001) The relationship between cannabis use, depression and anxiety among australian adults: findings from the national survey of mental health and well-being. Soc Psychiatry Psychiatr Epidemiol 36:219–227
Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O’Connor J, Russo M (2015) Proportion of patients in south london with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2:233–238
Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488–491
Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C (2013) Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40:1509–1517
Dorard G, Berthoz S, Phan O, Corcos M, Bungener C (2008) Affect dysregulation in cannabis abusers. Eur Child Adolesc Psychiatry 17:274–282
Duperrouzel J, Hawes SW, Lopez-Quintero C, Pacheco-Colón I, Comer J, Gonzalez R (2018) The association between adolescent cannabis use and anxiety: a parallel process analysis. Addict Behav 78:107–113
Dworkin ER, Kaysen D, Bedard-Gilligan M, Rhew IC, Lee CM (2017) Daily-level associations between ptsd and cannabis use among young sexual minority women. Addict Behav 74:118–121
Earleywine M, Barnwell SS (2007) Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J 4:11
Earleywine M, Bolles JR (2014) Marijuana, expectancies, and post-traumatic stress symptoms: a preliminary investigation. J Psychoact Drugs 46:171–177
ElSohly MA (2014) Potency monitoring program quarterly report no. 123—reporting period: 09/16/2013–12/15/2013. In: University of Missippi, National Center for Natural Products Research, Oxford, MS
ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the united states. Biol Psychiatry 79:613–619
Ersche KD, Williams GB, Robbins TW, Bullmore ET (2013) Meta-analysis of structural brain abnormalities associated with stimulant drug dependence and neuroimaging of addiction vulnerability and resilience. Curr Opin Neurobiol 23:615–624
Feingold D, Weiser M, Rehm J, Lev-Ran S (2016) The association between cannabis use and anxiety disorders: results from a population-based representative sample. Eur Neuropsychopharmacol 26:493–505
Feingold D, Weiser M, Rehm J, Lev-Ran S (2015) The association between cannabis use and mood disorders: a longitudinal study. J Affect Disord 172:211–218
Fergusson DM, Boden JM, Horwood LJ (2006) Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 101:556–569
Flórez-Salamanca L, Secades-Villa R, Budney AJ, García-Rodríguez O, Wang S, Blanco C (2013) Probability and predictors of cannabis use disorders relapse: results of the national epidemiologic survey on alcohol and related conditions (nesarc). Drug Alcohol Depend 132:127–133
Foti DJ, Kotov R, Guey LT, Bromet EJ (2010) Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 167:987–993
Frank B, Serpell M, Hughes J, Matthews J, Kapur D (2008) Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 336:199–201
Fraser GA (2009) The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (ptsd). CNS Neurosci Ther 15:84–88
Gage SH, Hickman M, Heron J, Munafò MR, Lewis G, Macleod J, Zammit S (2015) Associations of cannabis and cigarette use with depression and anxiety at age 18: findings from the avon longitudinal study of parents and children. PLoS One 10:e0122896
Galvez-Buccollini JA, Proal AC, Tomaselli V, Trachtenberg M, Coconcea C, Chun J, Manschreck T, Fleming J, Delisi LE (2012) Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res 139:157–160
George TP, Hill KP, Vaccarino FJ (2018) Cannabis legalization and psychiatric disorders: Caveat “hemp-tor”. Can J Psychiatry 63:447–450
Gieringer D, St. Laurent J, Goodrich S (2004) Cannabis vaporizer combines efficient delivery of thc with effective suppression of pyrolytic compounds. J Cannabis Ther 4:7–27
Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler K (2015) The association between cannabis abuse and subsequent schizophrenia: a swedish national co-relative control study. Psychol Med 45:407–414
Grant S, Pedersen ER, Neighbors C (2016) Associations of posttraumatic stress disorder symptoms with marijuana and synthetic cannabis use among young adult us veterans: a pilot investigation. J Stud Alcohol Drugs 77:509–514
Green B, Kavanagh D, Young R (2003) Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 22:453–460
Greer GR, Grob CS, Halberstadt AL (2014) Ptsd symptom reports of patients evaluated for the new mexico medical cannabis program. J Psychoact Drugs 46:73–77
Guttmannova K, Kosterman R, White HR, Bailey JA, Lee JO, Epstein M, Jones TM, Hawkins JD (2017) The association between regular marijuana use and adult mental health outcomes. Drug Alcohol Depend 179:109–116
Hall W, Weier M (2015) Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther 97:607–615
Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, Zhang H, Grant BF (2016) Prevalence and correlates of dsm-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions–iii. Am J Psychiatry 173:588–599
Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W (2007) Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 46:408–417
Helle S, Ringen PA, Melle I, Larsen T-K, Gjestad R, Johnsen E, Lagerberg TV, Andreassen OA, Kroken RA, Joa I (2016) Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (n = 1119). Schizophr Res 170:217–221
Hill KP (2015) Marijuana: the unbiased truth about the world’s most popular weed. Simon and Schuster, New York
Hill KP (2015) Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313:2474–2483
Hjorthøj C, Østergaard MLD, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, Nordentoft M (2015) Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry 2:801–808
Hodgson K, Almasy L, Knowles EE, Kent JW, Curran JE, Dyer TD, Göring HH, Olvera RL, Woolsey MD, Duggirala R (2017) The genetic basis of the comorbidity between cannabis use and major depression. Addiction 112:113–123
Horwood LJ, Fergusson DM, Coffey C, Patton GC, Tait R, Smart D, Letcher P, Silins E, Hutchinson DM (2012) Cannabis and depression: an integrative data analysis of four australasian cohorts. Drug Alcohol Depend 126:369–378
Iseger TA, Bossong MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162:153–161
Jetly R, Heber A, Fraser G, Boisvert D (2015) The efficacy of nabilone, a synthetic cannabinoid, in the treatment of ptsd-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585–588
Johnson MJ, Pierce JD, Mavandadi S, Klaus J, Defelice D, Ingram E, Oslin DW (2016) Mental health symptom severity in cannabis using and non-using veterans with probable ptsd. J Affect Disord 190:439–442
Kelley ME, Wan CR, Broussard B, Crisafio A, Cristofaro S, Johnson S, Reed TA, Amar P, Kaslow NJ, Walker EF (2016) Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr Res 171:62–67
Kevorkian S, Bonn-Miller MO, Belendiuk K, Carney DM, Roberson-Nay R, Berenz EC (2015) Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample. Psychol Addict Behav 29:633
Khantzian EJ (2012) Reflections on treating addictive disorders: a psychodynamic perspective. Am J Addict 21:274–279
Khantzian EJ (1997) The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 4:231–244
Kim S-W, Dodd S, Berk L, Kulkarni J, de Castella A, Fitzgerald PB, Kim J-M, Yoon J-S, Berk M (2015) Impact of cannabis use on long-term remission in bipolar i and schizoaffective disorder. Psychiatry Investig 12:349–355
Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24:97
Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3:760–773
Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J (2009) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36:1115–1130
Large M, Sharma S, Compton MT, Slade T, Nielssen O (2011) Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 68:555–561
Lee JY, Brook JS, Finch SJ, Brook DW (2018) Trajectories of cannabis use beginning in adolescence associated with symptoms of posttraumatic stress disorder in the mid-thirties. Subst Abuse 39:39–45
Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J (2013) Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry 54:589–598
Leweke F, Piomelli D, Pahlisch F, Muhl D, Gerth C, Hoyer C, Klosterkötter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94
Loflin M, Earleywine M (2014) A new method of cannabis ingestion: the dangers of dabs? Addict Behav 39:1430–1433
Lopez-Quintero C, de los Cobos JP, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C (2011) Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (nesarc). Drug Alcohol Depend 115:120–130
Lynskey M, Hall W (2000) The effects of adolescent cannabis use on educational attainment: a review. Addiction 95:1621–1630
Ma M, Coles AS, George TP (2018) Understanding and treating co-occurring bipolar disorder and substance use disorders. Psychiatric Times 35:8–9
Manhapra A, Stefanovics E, Rosenheck R (2015) Treatment outcomes for veterans with ptsd and substance use: impact of specific substances and achievement of abstinence. Drug Alcohol Depend 156:70–77
Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P (2014) Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol Med 44:2513–2521
Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42:1262–1269
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S (2017) Cannabidiol (cbd) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225–231
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD et al (2018) Cannabidiol (cbd) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225–231
Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci. https://doi.org/10.1073/nas.1206820109
Metrik J, Bassett SS, Aston ER, Jackson KM, Borsari B (2018) Medicinal versus recreational cannabis use among returning veterans. Transl Issues Psychol Sci 4:6
Metrik J, Jackson K, Bassett SS, Zvolensky MJ, Seal K, Borsari B (2016) The mediating roles of coping, sleep, and anxiety motives in cannabis use and problems among returning veterans with ptsd and mdd. Psychol Addict Behav 30:743
Moitra E, Anderson BJ, Stein MD (2016) Reductions in cannabis use are associated with mood improvement in female emerging adults. Depression Anxiety 33:332–338
Morrison P, Zois V, McKeown D, Lee T, Holt D, Powell J, Kapur S, Murray R (2009) The acute effects of synthetic intravenous δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39:1607–1616
Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN (2008) Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 9:254–264
National Academies of Sciences E, Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press, Washington, DC
Nunberg H, Kilmer B, Pacula RL, Burgdorf JR (2011) An analysis of applicants presenting to a medical marijuana specialty practice in california. J Drug Policy Anal. https://doi.org/10.2202/1941-2851.1017
Østergaard ML, Nordentoft M, Hjorthøj C (2017) Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality disorder. Addiction 112:1250–1259
Parsons LH, Hurd YL (2015) Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci 16:579
Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, Stewart R, McGuire P, Bhattacharyya S (2015) Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Lancet 385:S79
Piontek D, Kraus L, Bjarnason T, Demetrovics Z, Ramstedt M (2013) Individual and country-level effects of cannabis-related perceptions on cannabis use. A multilevel study among adolescents in 32 european countries. J Adolesc Health 52:473–479
Quello SB, Brady KT, Sonne SC (2005) Mood disorders and substance use disorder: a complex comorbidity. Sci Pract Perspect 3:13
Rabin RA, Barr MS, Goodman MS, Herman Y, Zakzanis KK, Kish SJ, Kiang M, Remington G, George TP (2017) Effects of extended cannabis abstinence on cognitive outcomes in cannabis dependent patients with schizophrenia vs non-psychiatric controls. Neuropsychopharmacology 42:2259–2271
Rabin RA, Kozak K, Zakzanis KK, Remington G, George TP (2018) Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophr Res 194:55–61
Rabin RA, Zakzanis KK, Daskalakis ZJ, George TP (2013) Effects of cannabis use status on cognitive function, in males with schizophrenia. Psychiatry Res 206:158–165
RachBeisel J, Scott J, Dixon L (1999) Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatr Serv 50:1427–1434
Rasic D, Weerasinghe S, Asbridge M, Langille DB (2013) Longitudinal associations of cannabis and illicit drug use with depression, suicidal ideation and suicidal attempts among nova scotia high school students. Drug Alcohol Depend 129:49–53
Ratheesh A, Cotton SM, Betts JK, Chanen A, Nelson B, Davey CG, McGorry PD, Berk M, Bechdolf A (2015) Prospective progression from high-prevalence disorders to bipolar disorder: exploring characteristics of pre-illness stages. J Affect Disord 183:45–48
Reinarman C, Nunberg H, Lanthier F, Heddleston T (2011) Who are medical marijuana patients? Population characteristics from nine california assessment clinics. J Psychoact Drugs 43:128–135
Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A (2014) Preliminary, open-label, pilot study of add-on oral δ 9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 34:587–591
Rotermann M, Langlois K (2015) Prevalence and correlates of marijuana use in canada, 2012. Statistics Canada Ottawa, Ontario
Sagar KA, Dahlgren MK, Racine MT, Dreman MW, Olson DP, Gruber SA (2016) Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood. PLoS One 11:e0157060
Sami MB, Rabiner EA, Bhattacharyya S (2015) Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. Eur Neuropsychopharmacol 25:1201–1224
Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, Camuri G, Altamura AC, Murray R, Bhattacharyya S (2016) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3:215–225
Schoeler T, Theobald D, Pingault J-B, Farrington DP, Coid JW, Bhattacharyya S (2018) Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: findings from 40 years of follow-up. Psychological Med 48(13):2169–2176
Scholes-Balog KE, Hemphill SA, Evans-Whipp TJ, Toumbourou JW, Patton GC (2016) Developmental trajectories of adolescent cannabis use and their relationship to young adult social and behavioural adjustment: a longitudinal study of australian youth. Addict Behav 53:11–18
Schuckit MA (2006) Comorbidity between substance use disorders and psychiatric conditions. Addiction 101:76–88
Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min S-J, Sakai JT (2014) Temporal trends in marijuana attitudes, availability and use in colorado compared to non-medical marijuana states: 2003–11. Drug Alcohol Depend 140:145–155
Sexton M, Cuttler C, Finnell JS, Mischley LK (2016) A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res 1:131–138
Sherva R, Wang Q, Kranzler H, Zhao H, Koesterer R, Herman A, Farrer LA, Gelernter J (2016) Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks. JAMA Psychiatry 73:472–480
Skrabek RQ, Galimova L, Ethans K, Perry D (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9:164–173
Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287:1123–1131
Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, Arnold LM, Amicone J (2007) Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 64:57–64
Swendsen J, Conway KP, Degenhardt L, Glantz M, Jin R, Merikangas KR, Sampson N, Kessler RC (2010) Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the national comorbidity survey. Addiction 105:1117–1128
Swendsen JD, Merikangas KR (2000) The comorbidity of depression and substance use disorders. Clin Psychol Rev 20:173–189
Tournier M, Sorbara F, Gindre C, Swendsen JD, Verdoux H (2003) Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. Psychiatry Res 118:1–8
Tull MT, McDermott MJ, Gratz KL (2016) Marijuana dependence moderates the effect of posttraumatic stress disorder on trauma cue reactivity in substance dependent patients. Drug Alcohol Depend 159:219–226
Van Dam NT, Bedi G, Earleywine M (2012) Characteristics of clinically anxious versus non-anxious regular, heavy marijuana users. Addict Behav 37:1217–1223
van der Pol P, Liebregts N, de Graaf R, ten Have M, Korf DJ, van den Brink W, van Laar M (2013) Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction 108:1459–1469
Van Laar M, Van Dorsselaer S, Monshouwer K, De Graaf R (2007) Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction 102:1251–1260
Van Os J, Bak M, Hanssen M, Bijl R, De Graaf R, Verdoux H (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156:319–327
Vandermeeren R, Hebbrecht M (2012) The dual process model of addiction. towards an integrated model? Tijdschrift voor psychiatrie 54:731–740
Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO (2015) Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA 313:2491–2493
Villagonzalo K-A, Dodd S, Ng F, Mihaly S, Langbein A, Berk M (2011) The relationship between substance use and posttraumatic stress disorder in a methadone maintenance treatment program. Compr Psychiatry 52:562–566
Volkow ND, Baler RD, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 370:2219–2227
Volkow ND, Li T-K (2004) Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci 5:963
Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, Holtzman S (2013) Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy 24:511–516
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313:2456–2473
Wilkinson ST, Stefanovics E, Rosenheck RA (2015) Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry 76:1174–1180
Wise RA, Koob GF (2014) The development and maintenance of drug addiction. Neuropsychopharmacology 39:254
Zorrilla I, Aguado J, Haro J, Barbeito S, Lopez Zurbano S, Ortiz A, Lopez P, Gonzalez-Pinto A (2015) Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatr Scand 131:100–110